Email this article Press-reliz Glioblastoma: novye gorizonty lekarstvennoy terapii
- Authors: - -
- Issue: Vol 11, No 4 (2009)
- Pages: 24
- Section: Articles
- URL: https://journals.rcsi.science/1815-1434/article/view/26795
- ID: 26795
Cite item
Full Text
Abstract
В России зарегистрировано новое показание к применению Авастина (бевацизумаба) – лечение рецидива глиобластомы. 18 ноября2009 г. в рамках XIII Российского онкологического конгресса состоялся симпозиум по проблемам лечения глиобластомы, на котором впервые в нашей стране были представлены результаты эффективности Авастина в лечении данного вида опухоли.
Keywords
Full Text
##article.viewOnOriginalSite##References
- Stupp R, Hegi M, Mason W et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC - NCIC trial. Lancet Oncol 2009; 10 (5): 459–66.
- Furnari F, Fenton T, Bachoo R et al. Malignant astrocytic glioma: genetics, biology, and paths to treatment. Genes Dev 2007; 21: 2683–710.
- Louis D. Molecular pathology of malignant gliomas. Annu Rev Pathol 2006; 1: 97–117.
- Zagzag D, Zhong H, Scalzitti J et al. Expression of hypoxia - inducible factor 1a in brain tumors: association with angiogenesis, invasion, and progression. Cancer 2000; 88 (11): 2606–18.
- Plate K, Breier G, Weich H et al. Vascular endothelial growth factor is a potential tumour angiogenesis factor in human gliomas in vivo. Nature 1992; 359: 845–8.
- Shweiki D, Itin A, Soffer D et al. Vascular endothelial growth factor induced by hypoxia may mediate hypoxia - initiated angiogenesis. Nature 1992; 359: 843–5.
- Kim K, Li B, Winer J et al. Inhibition of vascular endothelial growth factor - induced angiogenesis suppresses tumour growth in vivo. Nature 1993; 362 (6423): 841–4.
- Jain R. Normalization of tumor vasculature: An emerging concept in antiangiogenic therapy. Science 2005; 307: 58–62.
- Duda , Jain R, Willett C. Antiangiogenics: The potential role of integrating this novel treatment modality with chemoradiation for solid cancers. J Clin Oncol 2007; 25: 4033–42.
- Friedman H, Prados M, Wen P et al. Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J Clin Oncol 2009; Aug 31.
- Vredenburgh J, Wefel J, Cloughesy T et al. Clinical assessment of corticosteroid use and neurocognitive function in patients with glioblastoma at first or second relapse treated with bevacizumab in the BRAIN study. EJC 2009; 7 (Suppl.): 495–6.
